Patents by Inventor Michael J. Briskin
Michael J. Briskin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130022607Abstract: The present invention relates to isolated antibodies and antigen-binding fragments that selectively bind human MAdCAM.Type: ApplicationFiled: August 31, 2012Publication date: January 24, 2013Inventor: Michael J. Briskin
-
Patent number: 8277808Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof that bind naturally occurring human MAdCAM, wherein said naturally occurring human MAdCAM comprises a polypeptide with at least 90% sequence identity to SEQ ID NO:2 or SEQ ID NO:4, said naturally occurring human MAdCAM binds ?4?7, and wherein said isolated antibodies and antigen-binding fragments thereof inhibit binding of said naturally occurring human MAdCAM to human ?4?7, and wherein said antibody inhibits adhesion of RPMI 8866 cells to cells that express said human MAdCAM.Type: GrantFiled: April 3, 2007Date of Patent: October 2, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventor: Michael J. Briskin
-
Patent number: 7803904Abstract: The present invention relates to fusion proteins comprising a naturally occurring primate MAdCAM, wherein said naturally occurring primate MAdCAM binds ?4?7 integrin and has at least about 75% amino acid similarity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.Type: GrantFiled: February 12, 1996Date of Patent: September 28, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Michael J. Briskin, Douglas J. Ringler, Dominic Picarella, Walter Newman
-
Patent number: 7750137Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode naturally occurring primate MAdCAMs, wherein said nucleic acid encodes the polypeptide shown in FIG. 1 (SEQ ID NO:2), the polypeptide shown in FIG. 2 (SEQ ID NO:4), or the polypeptide shown in FIG. 3 (SEQ ID NO:6). The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a naturally occurring primate MAdCAM, wherein said nucleic acid encodes a polypeptide having an amino acid sequence as set forth in FIG. 1 (SEQ ID NO:2), FIG. 2 (SEQ ID NO:4), or FIG. 3 (SEQ ID NO:6); to host cells comprising such constructs, useful for the production of recombinant proteins; the use of nucleic acids and/or proteins in assays to identify inhibitors (e.g., antagonists) of primate MAdCAM function; and to antibodies reactive with primate MAdCAM, which are useful in in vitro methods, diagnostic and/or therapeutic applications.Type: GrantFiled: September 1, 1995Date of Patent: July 6, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventor: Michael J. Briskin
-
Patent number: 7208152Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a molecule expressed on the surface of a target cell.Type: GrantFiled: June 17, 2002Date of Patent: April 24, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu
-
Patent number: 7038018Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention further relates to a method of modulating a function of Bonzo, and to the use of the antibodies, antigen-binding fragments, targeting molecules and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: August 27, 2001Date of Patent: May 2, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu
-
Publication number: 20040023373Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode primate MAdCAMs, and to proteins or polypeptides referred to herein as isolated and/or recombinant primate MAdCAMs. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a primate MAdCAM of the present invention, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant proteins; the use of nucleic acids and/or proteins in assays to identify inhibitors (e.g., antagonists) of primate MAdCAM function; and to antibodies reactive with primate MAdCAM, which are useful in in vitro methods, diagnostic and/or therapeutic application.Type: ApplicationFiled: September 1, 1995Publication date: February 5, 2004Inventor: MICHAEL J. BRISKIN
-
Publication number: 20030165995Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a molecule expressed on the surface of a target cell.Type: ApplicationFiled: June 17, 2002Publication date: September 4, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu
-
Publication number: 20030082182Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode primate MAdCAMs, and to proteins or polypeptides referred to herein as isolated and/or recombinant primate MAdCAMs. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a primate MAdCAM of the present invention, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant proteins; the use of nucleic acids and/or proteins in assays to identify inhibitors (e.g., antagonists) of primate MAdCAM function; and to antibodies reactive with primate MAdCAM, which are useful in in vitro methods, diagnostic and/or therapeutic applications.Type: ApplicationFiled: May 21, 2001Publication date: May 1, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventor: Michael J. Briskin
-
Patent number: 6514497Abstract: Methods of modulating LERK-2-mediated cell adhesion, as well as methods of modulating angiogenesis and inflammation are described. Also described are agents such as antibodies which can modulate LERK-2-mediated cell adhesion, as well as methods of treating angiogenic diseases and inflammatory diseases.Type: GrantFiled: October 1, 1998Date of Patent: February 4, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Michael J. Briskin, Lily Zou
-
Publication number: 20020151026Abstract: The present invention relates to an isolated or recombinant nucleic acid which encodes a mammalian hyaluronan synthase (e.g. human). The present invention also relates to a host cell comprising the nucleic acid encoding mammalian hyaluronan synthase. The present invention also relates to a method for producing a mammalian hyaluronan synthase comprising introducing into a host cell a nucleic acid construct comprising a nucleic acid which encodes a mammalian hyaluronan synthase, whereby a recombinant host cell is produced having said coding sequence operably linked to at least one expression control sequence; and maintaining the host cells produced in a suitable medium under conditions whereby the nucleic acid is expressed. The present invention also relates to an antibody or functional portion thereof which binds mammalian hyaluronan synthase.Type: ApplicationFiled: October 19, 2001Publication date: October 17, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventor: Michael J. Briskin
-
Publication number: 20020147314Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode primate MAdCAMs, and to proteins or polypeptides referred to herein as isolated and/or recombinant primate MAdCAMs. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a primate MAdCAM of the present invention, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant proteins; the use of nucleic acids and/or proteins in assays to identify inhibitors (e.g., antagonists) of primate MAdCAM function; and to antibodies reactive with primate MAdCAM, which are useful in in vitro methods, diagnostic and/or therapeutic applications. The invention also relates to the treatment of individuals, particularly humans, suffering from a disease (e.g.Type: ApplicationFiled: September 8, 1997Publication date: October 10, 2002Inventors: MICHAEL J. BRISKIN, DOUGLAS J. RINGLER, DOMINIC PICARELLA, WALTER NEWMAN
-
Patent number: 6423514Abstract: The present invention relates to an isolated or recombinant nucleic acid which encodes a mammalian hyaluronan synthase (e.g. human). The present invention also relates to a host cell comprising the nucleic acid encoding mammalian hyaluronan synthase. The present invention also relates to a method for producing a mammalian hyaluronan synthase comprising introducing into a host cell a nucleic acid construct comprising a nucleic acid which encodes a mammalian hyaluronan synthase, whereby a recombinant host cell is produced having said coding sequence operably linked to at least one expression control sequence; and maintaining the host cells produced in a suitable medium under conditions whereby the nucleic acid is expressed. The present invention also relates to an antibody or functional portion thereof which binds mammalian hyaluronan synthase.Type: GrantFiled: April 22, 1996Date of Patent: July 23, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventor: Michael J. Briskin
-
Publication number: 20020090657Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR and HBMBU14) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a molecule expressed on the surface of a target cell.Type: ApplicationFiled: August 27, 2001Publication date: July 11, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu
-
Patent number: 6319675Abstract: The invention relates to a method of detecting and/or identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand and/or modulate a function of Bonzo.Type: GrantFiled: November 24, 1999Date of Patent: November 20, 2001Assignee: Millennium Pharmaceuticals, Inc.Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu